Drug intelligence / Profile preview

TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE

Development stage
Unknown
Modality
Small Molecules, Peptides
01

Overview

TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE is a synthetic peptide or peptidomimetic characterized by its complex chemical structure, which includes a guanidinomethyl-cyclohexane moiety, D-cyclohexylalanyl, L-azetidine-2-yl, D-tyrosinyl, and L-homoargininamide residues. The presence of guanidinium groups (from guanidinomethyl and homoargininamide) suggests potential interactions with negatively charged biological sites, often found in enzyme active sites or receptor binding pockets. The L-azetidine-2-yl residue is a proline analog, which can introduce conformational constraints and influence the secondary structure and stability of the peptide, thereby affecting its biological activity and interaction with target molecules. While the specific biological activity, primary indication, or developer of this compound are not readily available in public databases, its intricate design is typical of compounds developed for research into protein-ligand interactions, enzyme inhibition, or receptor modulation.

Other names
(2S)-N-[(2R)-1-[[(2S)-1-amino-6-(diaminomethylideneamino)-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-1-[(2R)-3-cyclohexyl-2-[[4-[(diaminomethylideneamino)methyl]cyclohexanecarbonyl]amino]propanoyl]azetidine-2-carboxamide
02

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call